Skip to content
Screener

Exelixis EXEL Unrealized Losses on Investments (Before Tax)

Unrealized Losses on Investments (Before Tax) at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
$1M—
Gilead Sciences logo
Gilead SciencesGILD
$1M—
Tango Therapeutics logo
Tango TherapeuticsTNGX
——
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
——

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$13.12B+30.3%
Enterprise value$13.01B+29.0%
P/E15.3×-1.5×
P/S5.4×+0.9×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemAmortized CostGross Unrealized GainsGross Unrealized LossesFair Value
Corporate bonds824,595740(2,424)822,911
U.S. Treasury and government-sponsored enterprises166,64254(622)166,074
Municipal bonds8,7154(14)8,705
Total debt securities available-for-sale1,158,264798(3,060)1,156,002
Cash575——575
Money market funds171,852——171,852
Certificates of deposit55,886——55,886
Total cash, cash equivalents and marketable securities$1,386,577$798$(3,060)$1,384,315

Item 1. Financial Statements.

FAQ

What is Exelixis's unrealized losses on investments (before tax)?
Exelixis (EXEL) reported unrealized losses on investments (before tax) of $3.06M in Q2 2026.
How has Exelixis's unrealized losses on investments (before tax) changed year-over-year?
Exelixis's unrealized losses on investments (before tax) increased by 349.3% year-over-year, from $681K to $3.06M.
What is the long-term trend for Exelixis's unrealized losses on investments (before tax)?
Over 5 years (2020 to 2025), Exelixis's unrealized losses on investments (before tax) has grown at a 25.9% compound annual growth rate (CAGR), from $12K to $38K.
What does unrealized losses on investments (before tax) mean?
The total unrealized losses on investments, typically related to available-for-sale securities, before considering tax effects.

Ask your AI about Exelixis's unrealized losses on investments (before tax).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude